Page 63 - GPD-4-1

Gene & Protein in Disease rs670 SNP in APOA1 gene

Table 1. (Continued)
Authors Study type Year Country n MAF Relative risk Odds ratio Conclusions
Vorobyeva et al. 59 Cross-sectional 2017 Russia 58 47% - - The polymorphic homozygote
genotype was associated with
the best response to statins
Wang et al. 60 Case–control 2017 China 424 17% - 1.34 (1.03 – 1.74); The polymorphic allele was
P = 0.026 associated with a higher risk of
low HDL-c
Wang et al. 61 Case–control 2017 China 812 28% - 2.28 (1.52 – 3.44); The polymorphic homozygote
P < 0.001 genotype was associated with a
higher risk of ischemic stroke
Hosseini-Esfahani Case–control 2017 Iran 414 29% - 1.11 (0.85 – 1.46); The polymorphic allele was
et al. 62 P = 0.443 not associated with the risk of
metabolic syndromes
Kovtun and Case–control 2018 Russia 69 24% - 2.14 (0.95 – 4.79); The polymorphic allele was
Ustyuzhanina 63 P = 0.066 not associated with the risk of
obesity and hypertension
Luis et al. 64 Cross-sectional 2018 Spain 63 15% - - The polymorphic allele was
associated with higher levels
of HDL-c and lower levels of
insulin and HOMA-IR
Wang et al. 65 Case–control 2018 China 1,433 16% - 1.34 (1.06 – 1.69); The polymorphic allele was
P = 0.014 associated with a higher risk of
dyslipidemia
Luis et al. 47 Clinical trial 2019 Spain 360 17% - - The polymorphic allele ligated
with the low-calorie diet with
high levels of polyunsaturated
fatty acids was associated with
higher levels of HDL-c and
lower levels of LDL-c, insulin,
and HOMA-IR
Ściskalska and Case–control 2022 Poland 44 37% - 1.54 (0.68 – 3.49); The polymorphic allele was
Milnerowicz 66 P = 0.304 not associated with the risk of
pancreatitis
Supajaree et al. 67 Cross-sectional 2022 Thailand 355 28% - - The polymorphic allele was
associated with higher levels
of HDL-c and lower levels of
hsCRP
Domínguez-Díaz Case–control 2022 Mexico 19 31% - 2.03 (0.69 – 5.92); The polymorphic allele was
et al. 68 P = 0.196 not associated with the risk of
benign breast disease
Casillas et al. 69 Case–control 2022 Mexico 130 31% - 1.77 (1.02 – 3.08); The polymorphic allele was
P = 0.042 associated with a higher risk of
myocardial infarction
Pérez-Beltrán Clinical trial 2023 Mexico 101 27% - - The polymorphic allele
et al. 70 predicted lower levels of
triglycerides and VLDL-c
Krishnamurthy Cross-sectional 2023 USA 184 19% - - The polymorphic allele was
et al. 71 associated with reduced
myeloperoxidase activity and
NT-pro-BNP levels
Abbreviations: HDL-c: High-density lipoprotein cholesterol; HOMA-IR: Homeostasis model assessment-estimated insulin resistance;
hsCRP: High-sensitivity C-reactive protein; LDL-c: Low-density lipoprotein cholesterol; MAF: Minor allele frequency; NT-pro-BNP: N-terminal
fragment brain natriuretic peptides; USA: United States of America; VLDL-c: Very low-density lipoprotein cholesterol; P-value refers to a relative risk
test or odds ratio for the presence of the polymorphic allele. Statistical significance P < 0.05.

Volume 4 Issue 1 (2025) 5 doi: 10.36922/gpd.4354